{
    "pmcid": "9656363",
    "qa_pairs": {
        "What is the primary target of the nanobodies developed in the study?": [
            "The receptor binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of the SARS-CoV-2 virus",
            "The membrane protein of the SARS-CoV-2 virus",
            "The envelope protein of the SARS-CoV-2 virus"
        ],
        "What potential application is suggested for nanobodies due to their small size and high affinity?": [
            "Inhalable aerosols for direct delivery to the respiratory system",
            "Intravenous injections for systemic delivery",
            "Topical creams for skin application",
            "Oral tablets for digestive absorption"
        ],
        "What was the capacity of the phage display library constructed in the study?": [
            "4.7 \u00d7 10^8 colony-forming units (CFU)",
            "3.2 \u00d7 10^9 colony-forming units (CFU)",
            "5.5 \u00d7 10^7 colony-forming units (CFU)",
            "6.8 \u00d7 10^8 colony-forming units (CFU)"
        ],
        "Which nanobody exhibited cross-reactivity with other coronavirus proteins?": [
            "Nb68",
            "Nb25",
            "Nb52",
            "Nb61"
        ],
        "Which nanobody showed the highest binding affinity to the SARS-CoV-2 S-RBD?": [
            "Nb61",
            "Nb25",
            "Nb52",
            "Nb68"
        ]
    }
}